WALTHAM, Mass., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) (“the Company”) today provided an update on injection kits supplied by Apellis and an update on the rare ...

Apellis Pharmaceuticals, a biotech drug company based in Waltham, Mass., recalled more than 61,000 injection needle kits after eight retinal vasculitis cases were reported. The company is pulling 12 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Apellis is exclusively distributing injection kits with ...

While nothing is certain yet, Apellis may be homing in on the source of a rare but serious side effect tied to its world-first geographic atrophy drug Syfovre. The safety update comes as the company ...

Support to the market growth comes from shift towards increased safety standards & compliance with more stringent regulatory requirements. Healthcare practitioners are rapidly incorporating filter ...

More than 100,000 vials have been distributed/administered between real world and clinical trials; since last update, confirmed one additional event of retinal ...